高级检索
当前位置: 首页 > 详情页

Development and Validation of a New Immune-Inflammatory-Nutritional Score to Predict Pathological Complete Response in Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy: A Two-Center Study

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China. [2]Institute of Breast Health Medicine, Department of Medical Oncology, Cancer Center, Breast Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
出处:
ISSN:

关键词: triple-negative breast cancer immune-inflammatory-nutritional score pathological complete response neoadjuvant chemotherapy nomogram

摘要:
To construct a novel immune-inflammatory-nutritional (IIN) score based on peripheral blood biomarkers related to inflammation, immunity, and nutrition, and to predict the efficacy of neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC).We retrospectively selected 431 patients with TNBC from Xijing Hospital, and then randomly divided the patients into a training set and an internal validation set in a ratio of 7:3. An external validation set was included with 154 patients selected from West China Hospital of Sichuan University. In the training set, patients were divided into the pathological complete response (pCR) group and the non-pathological complete response group. Univariate logistic regression analysis and LASSO regression analysis were used to select biomarkers that affect the efficacy of NAC in TNBC patients and to construct the IIN score. A nomogram model was constructed based on the IIN score and clinical pathological characteristics to predict whether TNBC patients could achieve pCR after NAC before treatment. The predictive performance and clinical application value of the nomogram model were assessed using the receiver operating characteristic (ROC) curve, calibration curve, decision curve analysis, and confusion matrix.Through LASSO regression analysis, 6 biomarkers were ultimately identified to construct the scoring system. A nomogram model was constructed based on the IIN score and clinical pathological characteristics, and the ROC curve showed the areas under the curve to be 0.827, 0.786, and 0.754 in the training set, internal validation set, and external validation set, respectively. Calibration curves, decision curves, and confusion matrices all demonstrated that the nomogram model exhibited robust predictive performance and holds certain clinical application value.The nomogram model based on the IIN score offers high predictive performance and can accurately predict the efficacy of NAC in TNBC patients before treatment, highlighting its clinical application potential.© 2025 Wang et al.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 3 区 医学
小类 | 3 区 免疫学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 免疫学
第一作者:
第一作者机构: [1]Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, People's Republic of China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Collagen Density Is Associated With Pathological Complete Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients [2]Early changes of platelet‑lymphocyte ratio correlate with neoadjuvant chemotherapy response and predict pathological complete response in breast cancer [3]Histologic Categorization of Desmoplastic Reaction in Triple-Negative Breast Cancer: Its Relevance to Neoadjuvant Chemoimmunotherapy Response and Tumor Biology [4]Deep learning-based predictive biomarker of pathological complete response to neoadjuvant chemotherapy from histological images in breast cancer. [5]Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer [6]Combining the tumor-stroma ratio with tumor-infiltrating lymphocytes improves the prediction of pathological complete response in breast cancer patients [7]Development and validation of a prediction model for recurrence based on ProMisE molecular classifier and immune-inflammatory-nutritional score in endometrial carcinoma: a retrospective multiple-center study [8]Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial. [9]Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer:A multicenter study [10]Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial

资源点击量:65780 今日访问量:0 总访问量:5151 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号